Glivec decision raises more questions about the Indian IP Office
The Indian IP Appeal Board's decision to reject a Novartis patent application relating to the Glivec anti-cancer treatment gets an extensive review on the Spicy IP blog. The board gives a number of reasons for the rejection, but one rings very…
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Register now
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.
Subscribe now